Good results for Merck's Sperm Quality Analyser (SQA):
This article was originally published in Clinica
Executive Summary
German company Merck KGaA's Sperm Quality Analyser performed well in a study at the Royal Surrey County Hospital in Guildford, UK, against WHO quality criteria. The study involved 50 measurements on a range of semen samples, including patients receiving chemotherapy, those who had undergone vasectomy and patients whose partners were undergoing intra-uterine insemination. Each sample was tested four times, with a mean SMI value taken. The SQA provides results in around 40 seconds, giving digital readings of the sperm motility index in three parameters: total concentration, percent motility and abnormal morphology.
You may also be interested in...
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.